GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer

Links shared publicly online about this topic.

759
total visits

GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Gynecologic Oncology Group (GOG) will initiate a Phase 2 clinical trial of elesclomol in combination with paclitaxel for the treatment of persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.

View full resource at news-medical.net

Tags: Cancer, Lung Cancer, Ovarian Cancer, Lung, Phase 2 Clinical Trial, Clinical Trial, Women's Health, News